Literature DB >> 12124980

Antisense MBD2 gene therapy inhibits tumorigenesis.

Andrew Slack1, Veronica Bovenzi, Pascal Bigey, M A Ivanov, Shyam Ramchandani, Sanjoy Bhattacharya, Benjamin tenOever, B Lamrihi, Daniel Scherman, Moshe Szyf.   

Abstract

BACKGROUND: Aberration in the pattern of DNA methylation is one of the hallmarks of cancer. We present data suggesting that dysregulation of MBD2, a recently characterized member of a novel family of methylated DNA binding proteins, is involved in tumorigenesis. Two functions were ascribed to MBD2, DNA demethylase activity and repression of methylated genes.
METHODS: Multiple antisense expression and delivery systems, transfection, electrotransfer and adenoviral were employed to demonstrate that MBD2 is essential in tumorigenesis, both ex vivo and in vivo.
RESULTS: Inhibition of MBD2 by antisense expression resulted in inhibition of anchorage-independent growth of antisense transfected cancer cells or cells infected with an adenoviral vector expressing MBD2 antisense. Xenograft tumors treated with an adenoviral vector expressing MBD2 antisense or xenografts treated with electrotransferred plasmids expressing MBD2 antisense showed reduced growth.
CONCLUSIONS: These results support the hypothesis that one or both of the functions described for MBD2 are critical in tumorigenesis and that MBD2 is a potential anticancer target. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124980     DOI: 10.1002/jgm.288

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  10 in total

1.  Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1.

Authors:  Dan Zhu; Stephen B Hunter; Paula M Vertino; Erwin G Van Meir
Journal:  Cancer Res       Date:  2011-07-01       Impact factor: 12.701

Review 2.  Adhesion GPCRs in Tumorigenesis.

Authors:  Gabriela Aust; Dan Zhu; Erwin G Van Meir; Lei Xu
Journal:  Handb Exp Pharmacol       Date:  2016

Review 3.  Epigenetic therapeutics in autoimmune disease.

Authors:  Moshe Szyf
Journal:  Clin Rev Allergy Immunol       Date:  2010-08       Impact factor: 8.667

4.  Plasmid injection and application of electric pulses alter endogenous mRNA and protein expression in B16.F10 mouse melanomas.

Authors:  L C Heller; Y L Cruz; B Ferraro; H Yang; R Heller
Journal:  Cancer Gene Ther       Date:  2010-08-13       Impact factor: 5.987

5.  Human GMDS gene fragment hypermethylation in chronic high level of arsenic exposure with and without arsenic induced cancer.

Authors:  Sarmishtha Chanda; Uma B Dasgupta; Debendranath Guha Mazumder; Jayita Saha; Bhaskar Gupta
Journal:  Springerplus       Date:  2013-10-24

6.  Methylated DNA binding domain protein 2 (MBD2) coordinately silences gene expression through activation of the microRNA hsa-mir-496 promoter in breast cancer cell line.

Authors:  Sebastian Alvarado; Joanne Wyglinski; Matthew Suderman; Stephen A Andrews; Moshe Szyf
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

7.  Electrotransfer of single-stranded or double-stranded DNA induces complete regression of palpable B16.F10 mouse melanomas.

Authors:  L Heller; V Todorovic; M Cemazar
Journal:  Cancer Gene Ther       Date:  2013-11-29       Impact factor: 5.987

8.  MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection.

Authors:  Wei Liu; Na Wang; Min Lu; Xiao-Juan Du; Bao-Cai Xing
Journal:  Mol Med Rep       Date:  2016-06-15       Impact factor: 2.952

9.  Cytosolic DNA Sensor Upregulation Accompanies DNA Electrotransfer in B16.F10 Melanoma Cells.

Authors:  Katarina Znidar; Masa Bosnjak; Maja Cemazar; Loree C Heller
Journal:  Mol Ther Nucleic Acids       Date:  2016-06-07       Impact factor: 10.183

10.  Tumor cell death after electrotransfer of plasmid DNA is associated with cytosolic DNA sensor upregulation.

Authors:  Katarina Znidar; Masa Bosnjak; Nina Semenova; Olga Pakhomova; Loree Heller; Maja Cemazar
Journal:  Oncotarget       Date:  2018-04-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.